HOUSE BILL 93

50th legislature - STATE OF NEW MEXICO - second session, 2012

INTRODUCED BY

Eleanor Chavez

 

 

 

 

 

AN ACT

RELATING TO CONTROLLED SUBSTANCES; AMENDING THE CONTROLLED SUBSTANCES ACT TO DESIGNATE ADDITIONAL SYNTHETIC CANNABINOIDS AND OTHER CHEMICALS AS SCHEDULE I CONTROLLED SUBSTANCES; DECLARING AN EMERGENCY.

 

BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF NEW MEXICO:

     SECTION 1. Section 30-31-6 NMSA 1978 (being Laws 1972, Chapter 84, Section 6, as amended) is amended to read:

     "30-31-6. SCHEDULE I.--The following controlled substances are included in Schedule I:

          A. any of the following opiates, including their isomers, esters, ethers, salts, and salts of isomers, esters and ethers, unless specifically exempted, whenever the existence of these isomers, esters, ethers and salts is possible within the specific chemical designation:

                (1) acetylmethadol;

                (2) allylprodine;

                (3) alphacetylmethadol;

                (4) alphameprodine;

                (5) alphamethadol;

                (6) benzethidine;

                (7) betacetylmethadol;

                (8) betameprodine;

                (9) betamethadol;

                (10) betaprodine;

                (11) clonitazene;

                (12) dextromoramide;

                (13) dextrorphan;

                (14) diampromide;

                (15) diethylthiambutene;

                (16) dimenoxadol;

                (17) dimepheptanol;

                (18) dimethylthiambutene;

                (19) dioxaphetyl butyrate;

                (20) dipipanone;

                (21) ethylmethylthiambutene;

                (22) etonitazene;

                (23) etoxeridine;

                (24) furethidine;

                (25) hydroxypethidine;

                (26) ketobemidone;

                (27) levomoramide;

                (28) levophenacylmorphan;

                (29) morpheridine;

                (30) noracymethadol;

                (31) norlevorphanol;

                (32) normethadone;

                (33) norpipanone;

                (34) phenadoxone;

                (35) phenampromide;

                (36) phenomorphan;

                (37) phenoperidine;

                (38) piritramide;

                (39) proheptazine;

                (40) properidine;

                (41) racemoramide; and

                (42) trimeperidine;

          B. any of the following opium derivatives, their salts, isomers and salts of isomers, unless specifically exempted, whenever the existence of these salts, isomers and salts of isomers is possible within the specific chemical designation:

                (1) acetorphine;

                (2) acetyldihydrocodeine;

                (3) benzylmorphine;

                (4) codeine methylbromide;

                (5) codeine-N-oxide;

                (6) cyprenorphine;

                (7) desomorphine;

                (8) dihydromorphine;

                (9) etorphine;

                (10) heroin;

                (11) hydromorphinol;

                (12) methyldesorphine;

                (13) methyldihydromorphine;

                (14) morphine methylbromide;

                (15) morphine methylsulfonate;

                (16) morphine-N-oxide;

                (17) myrophine;

                (18) nicocodeine;

                (19) nicomorphine;

                (20) normorphine;

                (21) pholcodine; and

                (22) thebacon;

          C. any material, compound, mixture or preparation that contains any quantity of the following hallucinogenic substances, their salts, isomers and salts of isomers, unless specifically exempted, whenever the existence of these salts, isomers and salts of isomers is possible within the specific chemical designation:

                (1) 3,4-methylenedioxy amphetamine;

                (2) 5-methoxy-3,4-methylenedioxy amphetamine;

                (3) 3,4,5-trimethoxy amphetamine;

                (4) bufotenine;

                (5) diethyltryptamine;

                (6) dimethyltryptamine;

                (7) 4-methyl-2,5-dimethoxy amphetamine;

                (8) ibogaine;

                (9) lysergic acid diethylamide;

                (10) marijuana;

                (11) mescaline;

                (12) peyote, except as otherwise provided in the Controlled Substances Act;

                (13) N-ethyl-3-piperidyl benzilate;

                (14) N-methyl-3-piperidyl benzilate;

                (15) psilocybin;

                (16) psilocyn;

                (17) tetrahydrocannabinols;

                (18) hashish;

                (19) synthetic cannabinoids, including:

                     (a) 1-[2-(4-(morpholinyl)ethyl]-3-(1-naphthoyl)indole (JWH-200);

                     (b) 1-butyl-3-(1-napthoyl)indole (JWH-073);

                     (c) 1-hexyl-3-(1-naphthoyl)indole (JWH-019);

                     (d) 1-pentyl-3-(1-naphthoyl)indole (JWH-018 and AM 678);

                     (e) 1-pentyl-3-(2-methoxyphenylacetyl) indole (JWH-250);

                     (f) cannabicyclohexanol (CP 47, 497 and homologues: 5-(1,1-dimethylheptyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol (CP-47,497); and 5-(1,

1-dimethyloctyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol;

                     (g) 6aR,10aR)-9-(hydroxymethyl)

-6,6-dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,

10a-tetrahydrobenzo[c]chromen-1-ol);

                     (h) dexanabinol, (6aS,10aS)

-9-(hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2-yl)

-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol;

                     (i) 1-pentyl-3-(4-chloro naphthoyl) indole (JWH-398);

                     (j) (2-methyl-1-propyl-1H-indol-3-yl)

-1-naphthalenyl-methanone; [and]

                     (k) 5-(1,1-dimethylheptyl)-2-(3-hydroxy cyclohexyl)-phenol;

                     (l) 1-pentyl-3-[1-(4-methoxynaphthoyl)]

indole (JWH-081);

                     (m) 1-pentyl-3-(4-methyl-1-naphthoyl)

indole (JWH-122);

                     (n) 1-(5-fluoropentyl)-3-(1-naphthoyl)

indole (AM2201);

                     (o) 1-(5-fluoropentyl)-3-(2-iodobenzoyl)

indole (AM694);

                     (p) 1-pentyl-3-[(4-methoxy)-benzoyl]indole

(SR-19 and RCS-4);

                     (q) 1-cyclohexylethyl-3-

(2-methoxyphenylacetyl) indole (SR-18 and RCS-8); and

                     (r) 1-pentyl-3-(2-chlorophenylacetyl)

indole (JWH-203);

                (20) 3,4-methylenedioxymethcathinone (Methylone);

                (21) 3,4-methylenedioxypyrovalerone (MDPV);

                (22) 4-methylmethcathinone (Mephedrone);

                (23) 4-methoxymethcathinone (Methedrone; Bk-PMMA);

                (24) 3-fluoromethcathinone; [and]

                (25) 4-fluoromethcathinone (fephedrone);

                (26) naphthylpyrovalerone (naphyrone);

(27) ethcathinone;

(28) 3,4-methylenedioxyethcathinone

(ethylone);

(29) beta-keto-N-methyl;

(30) 3,4-benzodioxyolybutanamine

(butylone);

(31) N,N-dimethylcathinone

(metamfepramone);

(32) alpha-pyrrolidinopropiophenone

(alpha-PPP);

(33) 4-methoxy-alpha-pyrrolidinopropiophenone

(MOPPP);

(34) 3,4-methylenedioxy-alpha-

pyrrolidinopropiophenone (MDPPP);

(35) alpha-pyrrolidinovalerophenone

(alpha-PVP); and

(36) 6,7-dihydro-5H-indeno(5,6-d)-1,3-

dioxal-6-amine) (MDAI);

          D. the enumeration of peyote as a controlled substance does not apply to the use of peyote in bona fide religious ceremonies by a bona fide religious organization, and members of the beta-keto-N-methyl-organization so using peyote are exempt from registration. Any person who manufactures peyote for or distributes peyote to the organization or its members shall comply with the 4-federal Comprehensive Drug Abuse Prevention and Control Act of 1970 and all other requirements of law;

          E. the enumeration of marijuana, tetrahydrocannabinols or chemical derivatives of tetrahydrocannabinol as Schedule I controlled substances does not apply to the use of marijuana, tetrahydrocannabinols or chemical derivatives of tetrahydrocannabinol by certified patients pursuant to the Controlled Substances Therapeutic Research Act or by qualified patients pursuant to the provisions of the Lynn and Erin Compassionate Use Act; and

          F. controlled substances added to Schedule I by rule adopted by the board pursuant to Section 30-31-3 NMSA 1978."

     SECTION 2. EMERGENCY.--It is necessary for the public peace, health and safety that this act take effect immediately.

- 9 -